

accommodations, are asked to notify the executive secretary.

A preliminary agenda is provided below. Relevant documents and publications about the test methods and the validation and acceptance criteria being discussed are available on the NICEATM/ICCVAM Web site at: <http://iccvam.niehs.nih.gov> (select Documents and Publications).

Preliminary Agenda

Scientific Advisory Committee on Alternative Toxicological Methods

December 5, 2002.

Salon C, Crystal Gateway Marriott (703–920–3230), 1700 Jefferson Davis Highway, Arlington, Virginia, Crystal City Metro Stop.

9:00 a.m.

Welcome and Introductions

Informational Overviews of NIEHS, NTP, NICEATM, and ICCVAM

ICCVAM Validation and Acceptance Criteria

Current Scientific Directions of the European Centre for Validation of Alternative Methods (ECVAM)

Linkage of Scientific Directions between ECVAM and ICCVAM

- Public comment

12:15 p.m.

Lunch break

1:15 p.m.

Test Method Submissions and Proposed Nomination and Prioritization Process

- Public comment

In-Vitro Acute Toxicity Testing Methods

- Public comment

In-Vitro Estrogen/Androgen Receptor Binding and Transcriptional Activation

Assays

- Public comment

Other Business

5:00 p.m.

Adjourn

A copy of the agenda, committee roster, and any additional information, when available, will be posted on the NTP Web site (<http://ntp-server.niehs.nih.gov>) or available upon request to the NTP Executive Secretary (contact information provided above). Following the meeting, summary minutes will be prepared and available through the NICEATM/ICCVAM Web site (<http://iccvam.niehs.nih.gov>) and upon request to the NTP Liaison and Scientific Review Office (contact information above).

Public Comment Welcome

Public input at this meeting is invited and time is set aside for the presentation of public comments on any agenda topic. Each organization is allowed one time slot per agenda topic. At least 7 minutes will be allotted to each speaker, and if time permits, may be extended to 10 minutes. In order to facilitate planning for this meeting, persons wishing to make an oral presentation are asked to notify the NTP Executive Secretary (contact information above) by November 28, 2002, and to provide their name, affiliation, mailing address, phone, fax, e-mail, and sponsoring organization (if any). Registration for oral comments will also be available on-site, although time allowed for presentation by on-site registrants may be less than that for pre-registered speakers and will be determined by the number of persons who register at the meeting.

Persons registering to make oral comments are asked, if possible, to provide a copy of their statement to the NTP Executive Secretary (contact information above) by November 28, to enable review by the SACATM and NIEHS/NTP staff prior to the meeting. Written statements can supplement and may expand the oral presentation. If registering on-site and reading from written text, please bring 50 copies of the statement for distribution to the SACATM and NIEHS/NTP staff and to supplement the record.

Persons may also submit written comments in lieu of making oral comments. Written comments should be sent to the NTP Executive Secretary and should be received by November 28 to enable review by the SACATM and NIEHS/NIH prior to the meeting. Persons submitting written comments should include their name, affiliation, mailing address, phone, fax, e-mail, and sponsoring organization (if any) with the document.

Dated: October 24, 2002.

Samuel Wilson,

Deputy Director, National Institute of Environmental Health Sciences.

[FR Doc. 02–27902 Filed 11–1–02; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2), notice

is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, Small Grants Program for Cancer Epidemiology (PAR–01–021) and Cancer Prevention Research (PAR–00–025).

Date: December 3–4, 2002.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn Select, 8120 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: C. Michael Kerwin, Ph.D., MPh, Scientific Review Administrator, Special Review & Logistics Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, Room 8057, MSC 8329, Bethesda, MD 20892–8329. (301) 496–7421. kerwinm@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: October 28, 2002.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 02–27895 Filed 11–01–02; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Board of Scientific Counselors, NHLBI.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural